Artichoke protein

Other Names

AgkináraAl-karsufaAlcachofaAlcachofraAlcarchofaAlcaucilAnghinareArdī shawkīArdi-chawkeArtichautArtichokeArtichoke thistleArtičokaArtischockeArtisjokArtisjokkArtiskokArtišokasArtisokkaArtišoksAtisôCarciofiniCarciofoCardoonCarxofaCynaraCynara cardunculus L. var. scolymusCynara cardunculus scolymusCynara cardunculus var. scolymusCynara scolymus L.French artichokeGemüseartischockeGlobe artichokeGreen artichokeHarshafaKarczochKharshafKhurshufKronaertskockaKronärtskockaScotch thistleScottish thistleTyosen-azamiWild artichokeYan ji tsai

Synopsis

Artichoke Protein (Cynara cardunculus var. scolymus)

1. Identity and Botanical Classification

1.1 Botanical and Accepted Scientific Names

The globe artichoke is currently classified as Cynara cardunculus L. subsp. scolymus (L.) Hayek, a revision of the older but still widely used synonym Cynara scolymus L. It is an ancient herbaceous perennial plant, originating from the Mediterranean area, which today is widely cultivated all over the world. It belongs to the family Asteraceae (formerly Compositae). Globe artichoke is a perennial plant in the Asteraceae, the same family as milk thistle (Silybum marianum), and is a cultivated hybrid of a thistle, probably Cynara cardunculus L.

The botanical name is derived in part from the tradition of fertilizing the plant with ashes (Latin: cinis, cineris), and partly from the Greek skolymos, meaning "thistle," from the spines found on the bracts that enclose the flower heads forming the edible portion of the plant. The name was also derived from "Kynara," an Aegean Island where it was cultivated first.

1.2 Natural Source and Plant Description

Cynara scolymus L. is an herbaceous plant originally from the western Mediterranean area, with Italy, Spain, and France being the main producers. The globe artichoke is a perennial thistle originating in the Mediterranean, particularly around Italy, Sicily, Sardinia, and parts of North Africa. It is a herbaceous plant which produces flowering stems of 1–2 m or more in length. The basal, lobate-bipinnatisect leaves are very large; the stem leaves may be pinnatisect or entire. The leaves are grey-green to silver in colour, and the underside is covered with a dense layering of fine hairs. The inflorescence is formed of purplish-blue flowers grouped in heads which have an involucre of several long bracts which may be spiny.

Globe artichoke is a perennial herbaceous crop, cultivated mainly for its immature inflorescences called heads, which are marketed either fresh or processed. Its production is concentrated in the Mediterranean area, especially in Italy, Spain, and France, while it has also spread to the American continent. Its estimated total world production for 2023 was 1,609,935 tons, with a 10% increase with respect to 2020 according to the FAOSTAT database.

1.3 Parts Used and Common Forms

Both the edible flowering head and the by-products generated during processing (outer bracts, leaves, and stem) are characterized by a high content of essential vitamins, minerals, and bioactive compounds. In the context of dietary supplements and nutritional products, artichoke protein refers to the protein fraction derived from these plant parts—most commonly from the leaves, receptacle (heart), and bracts.

Commercial preparations include:

Dried leaf powder: Powdered dried leaves are used mostly in the natural health industry.
Standardized dry extract (artichoke leaf extract, ALE): The quality of artichoke leaves (Cynarae folium) and artichoke leaves dry extract (Cynarae folii extractum siccum) is specified in the European Pharmacopoeia (Ph. Eur.).
Artichoke protein powder/isolate: A concentrated protein fraction produced by processing artichoke plant material, primarily aimed at the plant-based protein supplement market.
Tea infusion: Pour 150 ml of hot water over 1.5 g of finely chopped artichoke leaves and strain after 10 minutes.
Tinctures and liquid extracts: Hydroethanolic preparations of standardized concentration.

The HMPC (European Medicines Agency's Committee on Herbal Medicinal Products) has classified artichoke leaves as a traditional herbal medicinal product.

2. Nutritional and Protein Composition

2.1 Protein Content by Plant Part

The protein content of artichoke varies meaningfully by plant part. Proximate analysis of dried leaves of Cynara scolymus showed the following composition: dry matter (97.03% DW), ash (15.81% DW), carbohydrate (80.05% DW), protein (16.64% DW), lipids (3.41% DW), total sugars (1.97% DW), and dietary fiber (71.60% DW). For the edible head (capitulum), protein content is lower on a fresh-weight basis. The nutritional profile of the edible immature flower bud was determined; on a fresh weight basis, the total protein content of the Capuanella artichoke cultivar was higher in comparison with Italian National Institute of Research on Food and Nutrition (INRAN) reference values (3.08 g/100g vs. the INRAN figure).

2.2 Amino Acid Profile

Aromatic amino acids (phenylalanine and tyrosine) are the most abundant essential amino acids in the receptacle and bracts of artichoke, followed by valine, lysine, and leucine. All essential amino acids except methionine and cystine in artichoke receptacle and bracts are higher than those of the provisional pattern recommended by the FAO/WHO/UNU (1985). The results show that sulfur amino acids (methionine and cysteine) are the first limiting amino acids, and histidine was the second limiting amino acid for receptacle and bracts artichoke protein.

The total amino acid content in the globe artichoke head (2.83 g/100 g) was higher than that reported in INRAN artichoke tables (2.42 g/100 g). Asparagine was the main free amino acid, in line with its role as an N-mobilizer in plant species. This pattern of asparagine dominance among free amino acids, combined with the limiting nature of sulfur-containing amino acids, is an important consideration for protein quality assessment.

The relatively low methionine and cysteine content means that, like most plant proteins, artichoke protein is not complete in the same sense as animal proteins when evaluated by modern scoring methods such as the PDCAAS (Protein Digestibility-Corrected Amino Acid Score) or the newer DIAAS (Digestible Indispensable Amino Acid Score). The PDCAAS is the most widely accepted method and the official U.S. method for assessing protein quality; it compares the essential amino acid profile of a protein source to human requirements and then adjusts for digestibility. Scores range from 0.0 (very poor quality) to 1.0 (high quality). No peer-reviewed PDCAAS or DIAAS score specific to artichoke protein isolate has been established in the published literature at the time of writing; such a score would be limited primarily by its sulfur amino acid deficit.

2.3 Co-occurring Nutrients

Nutritionally, the artichoke head contains fat, carbohydrates, and protein. It also contains fiber (inulin), calcium, phosphorus, potassium, folic acid, vitamin C, niacin, thiamine, trace minerals, and carotenoids. Macroelement concentrations in artichoke leaf extract can be presented in descending order as follows: K > P > Ca > Mg > Na. Microelement content in the extract follows: Zn > Fe > Cr > Mn.

3. Traditional and Historical Use

3.1 Ancient Mediterranean Civilizations

This plant has been appreciated by the ancient Egyptians, Greeks, and Romans, who used it both as a food and as a medicine, for their beneficial effects against hepato-biliary diseases and as a digestive aid. Artichoke cultivation traces back to ancient Mediterranean civilizations—Greeks, Romans, Egyptians. The Roman scholar Pliny the Elder described artichokes around 77 CE, praising their digestive virtues. In Rome, the artichoke was an important menu item at feasts.

3.2 European Folk and Herbal Medicine

Globe artichoke represents an important component of the Mediterranean diet, and is a rich source of bioactive phenolic compounds, and also inulin, fiber, and minerals. Artichoke leaf extracts have long been used in folk medicine, particularly for liver complaints.

Artichoke leaf has been used as a gallbladder and kidney stimulant in traditional European medicine since Roman times. Traditional medicinal uses of artichoke have focused on liver function. Artichoke leaf is considered choleretic (bile-increasing), hepatoprotective, cholesterol-reducing, and a diuretic. In Germany, it is used today as a gallbladder stimulant and for its lipid-lowering, liver-stimulating actions.

Bitters like artichoke were among the most valued remedies in ancient medicine. They were experienced as stimulating appetite and switching on a wide range of key digestive functions, including increasing bile clearance from the liver. Many of these reputations are now being supported by new research on the role of bitter receptors in the mouth and elsewhere in the body.

3.3 Preparation Methods in Traditional Use

Traditional preparations of artichoke for medicinal purposes included decoctions and infusions of the dried leaf, whole-plant food consumption, and later tinctures. This plant is a common component of the Mediterranean diet and has been used as a remedy for health conditions since antiquity. The leaf, rather than the edible flower head, was the predominant part used in European herbal traditions for therapeutic purposes, a practice that informed the development of modern standardized extracts.

4. Key Constituents and Active Compounds

4.1 Overview of Bioactive Phytochemicals

The leaves represent a great source of phenolic acids derived from caffeoylquinic acid or flavonoids such as luteolin and apigenin, while the head and stem contain a high content of soluble and insoluble dietary fiber, especially inulin and pectins. Artichoke leaves contain caffeoylquinic acids (including chlorogenic acid), flavonoids, and sesquiterpene bitter compounds.

4.2 Cynarin (1,3-O-Dicaffeoylquinic Acid)

Cynarin is the compound most historically associated with artichoke's medicinal activity. The therapeutic properties of artichoke leaf extracts have often been ascribed to the cynarin (1,3-O-dicaffeoylquinic acid) content of these extracts. Cynarin has been shown to be effective as a hypolipidemic remedy in a number of clinical studies. Cynarin seems to stimulate bile secretion by liver cells and increase the excretion of cholesterol and solid matter in bile.

4.3 Chlorogenic Acid and Caffeoylquinic Acids

Chlorogenic acid and cynarin, which are caffeic acid derivatives, in conjunction with luteolin, are antioxidant compounds found in artichoke leaf extract that most probably modulate hepatic pathways. All investigated individual artichoke compounds—chlorogenic acid, cynarin, luteolin, luteolin-7-O-glucoside—showed a remarkable antioxidative effect, with chlorogenic acid being the strongest antioxidant compound. Moreover, chlorogenic acid showed a strong, dose-dependent linear HMG-CoA reductase inhibitory effect at concentrations between 5 and 50 mg/mL.

4.4 Flavonoids: Luteolin, Luteolin-7-O-Glucoside, Apigenin

Flavonoids (0.1% to 1%), including flavone glycosides and rutin, are present in artichoke. Luteolin and its glycoside (luteolin-7-O-glucoside, also called cynaroside) are especially well-studied. The inhibition of non-saponifiable neutral lipid biosynthesis from 14C-acetate—a proxy for HMG-CoA reductase inhibition—appears to be attributed to the effects of chlorogenic acid, luteolin, and cynaroside.

4.5 Sesquiterpene Lactones (Cynaropicrin)

Bitter sesquiterpene principles such as grosheimin, cynaratriol, and cynaropicrin have been reported, as well as dehydrocynaropicrin, grosulfeimin, and related guaianolides, and cynarolide. These bitter principles are largely responsible for artichoke's appetite-stimulating and choleretic properties when consumed.

4.6 Inulin and Dietary Fiber

Artichoke contains highly polymerised inulin (with a degree of polymerisation up to 200), which has been shown to specifically promote the growth of bifidobacteria in the human digestive tract. This gives artichoke notable prebiotic properties, making it a valuable dietary component.

5. Mechanisms of Action

5.1 Choleretic Effect (Bile Stimulation)

The most consistently documented mechanism of artichoke extract is its ability to stimulate bile production and flow. Cynarin seems to stimulate bile secretion by liver cells and increase the excretion of cholesterol and solid matter in bile. The bioactive components of artichoke, in particular luteolin and its glycosides, stimulate the formation and excretion of bile, improving the functioning of the bile ducts. Preclinical studies have shown that artichoke activates bile ducts and improves bile flow even in conditions of bile stasis.

5.2 HMG-CoA Reductase Inhibition

The active components of artichoke, such as cynarin and luteolin, partially inhibit the enzyme HMG-CoA reductase, which is key in cholesterol synthesis. This inhibition is quantitatively distinct from that produced by pharmaceutical statins. Artichoke, at 0.25 ng/mL, appears to inhibit the HMG-CoA reductase enzyme by approximately 30% (with atorvastatin as active control reducing activity by 50% at this concentration). Some research suggests that artichoke leaf compounds may help inhibit HMG-CoA reductase, which plays a key role in the body's production of cholesterol. While this effect is milder than that of pharmaceutical statins, it contributes to the extract's overall cholesterol-managing benefits when combined with its effects on bile production and cholesterol elimination.

5.3 Antioxidant and Hepatoprotective Activity

Cynarin and caffeic acid per se show significant hepatoprotective activity in cultured rat hepatocytes. Interestingly, the hepatoprotective activity of cynarin can be more remarkable than silybin from the herbal medicine Silybum marianum, a plant known to improve liver parameters in humans. The high content of bioactive compounds provides artichoke a high antioxidant power due to the modulation effect of the transcription factor Nrf2, which may lead to protection against cardiovascular, hepatic, and neurological disorders.

5.4 Anti-inflammatory Activity

Different studies demonstrate that oxidative stress is the leading cause of the onset and progression of major human health disorders such as cardiovascular, neurological, metabolic, and cancer diseases. The large amount of polyphenol found in C. scolymus has antioxidant activity, enabling it to neutralize free radicals, preventing cellular damage. Various studies have demonstrated artichoke's potential as an anti-inflammatory, lipid-lowering, antimicrobial, and neuroprotective agent due to its phytochemical composition.

5.5 CYP Enzyme Interactions

Research indicates that artichoke leaf extract inhibits the activity of cytochrome P450 (CYP) 2B6 and cytochrome P450 (CYP) 2C19 in vitro. These in vitro findings have not yet been fully characterized in human pharmacokinetic studies, so their clinical significance for drug interactions remains to be determined.

6. Scientific Evidence by Area of Use

6.1 Lipid-Lowering and Cardiovascular Effects

Overview: This is the most extensively researched clinical area for artichoke extract. A literature search in PubMed identified 119 studies describing effects across 17 health benefits of artichoke; antioxidant activity and effects on the liver and lipid profile are the main health-promoting properties of this plant.

Meta-analytic evidence: Meta-analysis of data from 9 trials including 702 subjects suggested a significant decrease in plasma concentrations of total cholesterol. Supplementation with artichoke extract was associated with a significant reduction in both total cholesterol and LDL-C, and triglycerides, suggesting that supplementation may be synergistic with lipid-lowering therapy in patients with hyperlipidemia. No significant alteration in plasma HDL-C concentrations was observed (WMD: 1.0 mg/dL, 95% CI: −1.1, 3.1, p = 0.333). A significant association between the LDL-lowering effect of artichoke and baseline LDL-C concentrations was observed, suggesting a greater effect in individuals with higher baseline LDL.

Key individual RCTs:

Bundy et al. (2008), double-blind RCT: Plasma total cholesterol decreased in the treatment group by an average of 4.2% (from 7.16 to 6.86 mmol/L) and increased in the control group by an average of 1.9% (from 6.90 to 7.03 mmol/L), the difference between groups being statistically significant (p=0.025). No significant differences between groups were observed for LDL cholesterol, HDL cholesterol, or triglyceride levels. ALE consumption resulted in a modest but favourable statistically significant difference in total cholesterol after 12 weeks. In comparison with a previous trial, the apparent positive health status of the study population may have contributed to the modesty of the observed response.
Rondanelli et al. (2013), double-blind RCT: The study evaluated the effects of artichoke leaf extract (ALE) supplementation (250 mg, twice daily) on lipid pattern. A randomized, double-blind, placebo-controlled clinical trial was performed on 92 overweight subjects with primary mild hypercholesterolaemia for 8 weeks. Verum supplementation was associated with a significant increase in mean HDL-cholesterol (p < 0.001). A significantly decreased difference was also found for total cholesterol (p = 0.033), LDL-cholesterol (p < 0.001), total cholesterol/HDL ratio (p < 0.001), and LDL/HDL ratio (p < 0.001) when verum and placebo treatment were compared.

Dosage range reported in lipid studies: Rangboo et al. and Englisch et al. found improvements in lipid profile and liver biomarkers induced by the administration of 1800 to 2700 mg/day of ALE. The daily administration of approximately 2–3 g of artichoke leaf extract is seen as effective for improvements in lipid profile, evidenced as decreased LDL, triglycerides, and total cholesterol blood levels, but apparently no changes to HDL levels in some studies.

Evidence strength: The lipid-lowering evidence is among the most robust for any area of artichoke research. However, additional long-term clinical trials are pivotal to fully elucidate the potential effects of ALE administration on positive cardiovascular outcomes. Studies vary in extract standardization, dosage, and population, limiting direct comparison.

6.2 Hepatoprotection and Liver Health

Overview: Artichoke leaf extract was one of the few herbal remedies for which clinical and experimental trials have complemented each other. Both experimental and clinical effects have been verified through extensive biomedical research. Specifically, antioxidant, choleretic, hepatoprotective, bile-enhancing, and lipid-lowering effects have been demonstrated, which corresponded with its historical use.

NASH/NAFLD trial: Based on recent basic and clinical investigations, the extract of artichoke leaf has been revealed to be used for hepatoprotective and cholesterol-reducing purposes. One study aimed to assess the therapeutic effects on biochemical and liver biomarkers in patients with nonalcoholic steatohepatitis (NASH). In a randomized double-blind clinical trial, 60 consecutive patients suffering NASH were randomly assigned to receive Cynara scolymus extract (as 6 tablets per day consisting of 2700 mg extract of the herb) as the intervention group or placebo as the control group for two months. Comparing changes in study markers following interventions showed improvement in liver enzymes. The levels of triglycerides and cholesterol were significantly reduced in the group treated with Cynara scolymus when compared to the placebo group. Multivariate linear regression models indicated higher improvement in liver enzymes and also lipid profile, particularly triglycerides and total cholesterol, following administration of Cynara scolymus in comparison with placebo.

Animal evidence: In animal studies, liquid extracts of the roots and leaves of artichoke have demonstrated an ability to protect the liver, with possibly even an ability to help liver cells regenerate.

Evidence strength: Evidence for hepatoprotection is mechanistically plausible and supported by in vitro, animal, and limited clinical data. However, the number of well-powered human RCTs specifically for liver endpoints remains small. Although artichoke has been consumed safely for centuries as a food, standardized supplements and extracts require further investigation to fully characterize their long-term safety and potential interactions with medications.

6.3 Functional Dyspepsia and Digestive Health

Clinical trials: Indications for use supported by clinical studies (authorization) include dyspeptic complaints, especially in functional disorders of the bile ducts.

Giacosa et al. (2015), multicentre double-blind RCT (PMC4411465): A prospective multicentre, double-blind, randomized, placebo-controlled, parallel-group comparison of the supplement (ginger + artichoke extract) and placebo over a period of 4 weeks was performed. Two capsules/day were supplied (before lunch and dinner) to 126 FD patients (supplementation/placebo: 65/61). After 14 days of treatment, only the supplementation group showed a significant amelioration in symptom score. The improvement was significantly higher in the supplementation group than in placebo. The association between ginger and artichoke leaf extracts appeared safe and efficacious in the treatment of FD and could represent a promising treatment for this disease.

IBS evidence: In one study, a specific artichoke leaf extract (Hepar-SL forte, Serturner Arzneimittel GmbH) reduced abdominal pain and cramping, bloating, gas, and constipation associated with IBS after 6 weeks of treatment. In another study, a different specific artichoke leaf extract (Cynara SL, Lichtwer Pharma) reduced the occurrence of IBS symptoms in patients with heartburn by about 26%.

Artichoke (Cynara scolymus) is a herb with promising effects on quality of life of functional dyspepsia patients. Recent human clinical trials of artichoke preparations have documented health benefits associated with improvement of gastrointestinal symptoms related to functional dyspepsia and irritable bowel syndrome (IBS).

Evidence strength: The digestive/dyspepsia evidence is moderately supported by human clinical data, though many trials used combination products (e.g., artichoke + ginger) and involve small sample sizes, limiting definitive attribution to artichoke alone. ESCOP monograph recognition supports the traditional use rationale.

6.4 Prebiotic and Gut Microbiome Effects

Currently, inulin is researched for its benefits as a prebiotic, which may promote beneficial bacteria found in the gastrointestinal system. Artichoke contains highly polymerised inulin (with a degree of polymerisation up to 200), which has been shown to specifically promote the growth of bifidobacteria in the human digestive tract. This gives artichoke notable prebiotic properties, making it a valuable dietary component. The prebiotic effect is attributable to the inulin fraction accompanying the protein in whole artichoke preparations, not to the protein per se.

6.5 Antioxidant Activity

In various pharmacological test systems, artichoke leaf extracts have exhibited hepatoprotective, anticarcinogenic, antioxidative, and antibacterial properties. Antioxidant, choleretic, hepatoprotective, bile-enhancing, and lipid-lowering effects have been demonstrated. The antioxidant activity is most robustly documented in vitro and in animal models; human data are more limited but consistent with the mechanistic picture.

6.6 Blood Glucose and Metabolic Effects

Some studies show that consuming artichokes as part of a larger meal can help moderate post-meal blood sugar spikes, especially in individuals of a healthy weight. This may aid in the prevention of insulin resistance. A report demonstrated that artichoke aqueous leaf extract reduced serum total cholesterol, triglycerides, very low density lipoprotein, glucose levels, and plasma malondialdehyde (MDA) levels in streptozotocin-treated diabetic rats. Human evidence for glycemic effects remains preliminary and largely from animal or mechanistic studies.

7. Artichoke as a Supplemental Protein Source

7.1 Context as a Plant Protein

Artichoke fruits are notable for their relatively high protein and fiber content compared to other vegetables. In the context of the commercial supplement market, artichoke protein powder is produced from the concentrated protein fraction of artichoke plant material and positioned as a plant-based protein source. Artichoke protein powder is generally well-tolerated and easily digestible. It does not contain lactose or dairy, which makes it a suitable option for individuals who are lactose intolerant or have sensitivities to dairy products.

7.2 Amino Acid Profile in the Supplement Context

Artichoke protein powder contains a balanced profile of essential amino acids. While it may not have the same high levels of branched-chain amino acids (BCAAs) as whey protein isolate, it can still contribute to muscle building, repair, and overall health. Artichoke protein powder is notably high in arginine, an amino acid that plays a vital role in various physiological processes, including wound healing and blood vessel dilation.

As established above, the primary limiting amino acids are methionine and cysteine. Sulfur amino acids (methionine and cysteine) are the first limiting amino acids, and histidine is the second limiting amino acid for artichoke receptacle and bracts protein. Formulators frequently blend artichoke protein with complementary plant proteins (e.g., rice protein, which is higher in sulfur amino acids) to improve the overall amino acid score of the blend.

7.3 Protein Quality Considerations

The PDCAAS is the most widely accepted and official U.S. method for assessing protein quality; it compares the essential amino acid profile of a protein source to human requirements and then adjusts for digestibility. Scores range from 0.0 (very poor quality) to 1.0 (high quality). Most plant proteins score lower than animal proteins on PDCAAS, typically ranging from 0.4 to 0.9, meaning only 40–90% of the protein consumed is actually available for use after digestion. No formally published PDCAAS score specific to artichoke protein isolate has been identified in the peer-reviewed literature; the score would be constrained by its sulfur amino acid deficit.

8. Dosage Forms and Doses Reported in Studies

Dosages reported below are drawn directly from published studies and pharmacopeial references; they do not represent recommendations.

Tea infusion (traditional/ESCOP/EMA dosing): Drink a cup of artichoke leaf tea before meals; daily dose: 3 to 6 g of the herbal drug. Pour 150 ml of hot water over 1.5 g of finely chopped artichoke leaves and strain after 10 minutes.
Concentrated dry extract (ESCOP/EMA): The recommended daily dose (ESCOP/EMA) is equivalent to 5 to 10 g of dried leaves; concentrated dry extract: 600 mg to 1800 mg.
NASH/liver trial dose: 6 tablets per day consisting of 2700 mg extract of the herb for two months.
Lipid-lowering trial dose (Rondanelli et al.): 250 mg, twice daily (500 mg/day total) for 8 weeks in overweight subjects with mild hypercholesterolaemia.
Lipid-lowering effective range (review): 1800 to 2700 mg/day of ALE found to produce improvements in lipid profile and liver biomarkers; approximately 2–3 g of artichoke leaf extract per day is seen as effective for improvements in lipid profile.

9. Body Systems and Health Areas of Association

Hepatobiliary system: Choleretic (bile-stimulating), hepatoprotective effects; use in functional biliary disorders and NASH.
Cardiovascular system: Lipid-lowering (total cholesterol, LDL, triglycerides); HMG-CoA reductase inhibition; antioxidant protection of vascular tissue.
Digestive/gastrointestinal system: Relief of functional dyspepsia, bloating, flatulence, nausea; IBS symptom reduction; prebiotic effects via inulin.
Metabolic system: Preliminary evidence for glycemic modulation; support in metabolic syndrome context.
Musculoskeletal/sports nutrition context: As a plant-based protein source contributing to amino acid supply, with caveats around limiting sulfur amino acids.

Although research is not yet conclusive, scientists were optimistic that artichoke's long-standing use in humans for digestive and bowel problems was indeed justified. It may also play a role in lowering cholesterol and thus help to prevent heart disease.

10. Safety, Contraindications, and Drug Interactions

10.1 General Safety Profile

Artichoke heads are generally recognized as safe (GRAS) when used as food. Mild, transient, and infrequent adverse reactions, generally limited to GI complaints such as bloating and flatulence, have been reported. Very rarely, mild diarrhea and associated upper abdominal discomfort, nausea, and heartburn have been reported.

It was reported that artichoke extract was very safe to the human body as no obvious side effects were observed after continuous medication for several months.

10.2 Contraindications

Bile duct obstruction and gallstones: Artichoke leaves must not be taken in the presence of bile duct obstruction and gallstones or liver disease. Due to its bile-stimulating (choleretic) effect, artichoke products should not be used by individuals with bile duct obstruction, including those with gallstones, as they could exacerbate symptoms or lead to complications.
Allergy to Asteraceae/Compositae family: Artichoke may cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many others. Allergic reactions including anaphylaxis, bronchial asthma, and irritant contact dermatitis, as well as a case of hepatotoxicity, have been reported.
Pregnancy and lactation: There are no safety studies on the use of artichoke leaves during pregnancy and lactation; use in children under 12 years of age is not recommended due to lack of data. Information regarding safety and efficacy of artichoke leaf extract in pregnancy and lactation is lacking; caution is warranted.

10.3 Drug Interactions

CYP enzyme inhibition: Research indicates that artichoke leaf extract inhibits the activity of cytochrome P450 (CYP) 2B6 and cytochrome P450 (CYP) 2C19 in vitro. The in vitro nature of this finding means that clinical significance for co-administered medications metabolized by these enzymes has not been definitively established.
Hepatically metabolized drugs: Some medications are changed and broken down by the liver. Artichoke might change how quickly the liver breaks down these medications.
Colchicine: Artichoke may increase the serum concentration of colchicine. Monitor therapy.

10.4 Occupational and Contact Allergy

Allergic reactions have been reported, particularly in occupational exposure settings, where individuals handling fresh or dried artichoke plants have experienced eczema-like skin reactions. However, the prevalence of such reactions remains unclear. The possibility of cross-reactivity between artichoke and other plants of the Asteraceae family has not been reported in formal cross-reactivity studies. While no cases of oral allergic reactions to ingested artichoke have been documented, caution is advised in sensitive individuals.

11. Regulatory and Pharmacopeial Status

The quality of artichoke leaves (Cynarae folium) and artichoke leaves dry extract (Cynarae folii extractum siccum) is specified in the European Pharmacopoeia (Ph. Eur.). The HMPC has classified artichoke leaves as a traditional herbal medicinal product. The monograph is also covered by ESCOP (2nd edition), WHO monographs (Vol. 4), and the German Commission E. At the recommended amount and according to the German Commission E Monograph, there are no known side effects or drug interactions. ESCOP indications include: digestive disorders (e.g., stomach ache, nausea, vomiting, feeling of fullness, flatulence) and hepatobiliary complaints.

12. Evidence Summary and Research Gaps

Artichoke leaf extract is one of the few herbal remedies for which clinical and experimental trials have complemented each other. Both experimental and clinical effects have been verified through extensive biomedical research. The strongest and most replicated body of evidence pertains to lipid-lowering effects (total cholesterol, LDL, triglycerides), hepatoprotective effects in the setting of NASH/NAFLD, and relief of functional dyspepsia. The antioxidant and anti-inflammatory data are robust in vitro but require more large-scale human confirmation.

As a protein supplement specifically, artichoke protein remains an emerging category with limited dedicated clinical research. Its primary protein-quality limitation is the relatively low content of sulfur amino acids (methionine and cysteine). Its non-protein bioactive constituents (cynarin, chlorogenic acid, luteolin, inulin) contribute additional biological activity beyond simple amino acid delivery.

Key research gaps include: (1) formal PDCAAS/DIAAS characterization of commercially available artichoke protein isolates; (2) long-term cardiovascular outcome trials; (3) well-powered human studies on glycemic and metabolic effects; (4) robust pharmacokinetic studies on CYP-mediated drug interactions in humans; and (5) comparative clinical trials between artichoke protein and other plant protein sources for muscle protein synthesis outcomes.

References

Health Conditions

Health conditions that Artichoke protein may help support.

No conditions available.

Body Systems

Body systems that Artichoke protein may help support.

No body systems available.